When did the FDA approve the first generic versions of GILOTRIF (afatinib)?

On July 14, 2026, the U.S. Food and Drug Administration approved the first generic versions of GILOTRIF (afatinib tablets). These generics are indicated for metastatic non‑small cell lung cancer with specific EGFR mutations and for patients whose squamous NSCLC has progressed after platinum‑based chemotherapy.